Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Monkeypox
Interventions
JYNNEOS
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 50 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 13 more
Conditions
Monkey Pox
Interventions
Online module
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

New York City Observational Study of Mpox Immunity

NCT05654883
Conditions
Monkeypox, Mpox, HIV
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Terminated Phase 3 Interventional Results available

Study of Tecovirimat for Human Mpox Virus

NCT05534984
Conditions
MPOX
Interventions
Tecovirimat Oral Capsule, Placebo for Tecovirimat, Tecovirimat Oral Capsule (Open Label)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 30 more
Withdrawn Phase 1 Interventional Accepts healthy volunteers

SIGA-246 to Treat Smallpox

NCT00303225
Conditions
Vaccinia
Interventions
Vaccine: SIGA-246
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Monkeypox
Interventions
JYNNEOS
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
8
States / cities
San Diego, California • Washington D.C., District of Columbia • Decatur, Georgia + 5 more
Conditions
Monkeypox, HIV Infections, AIDS
Interventions
Not listed
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Monkeypox
Interventions
BNT166a
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
4
States / cities
San Diego, California • Kansas City, Missouri • Knoxville, Tennessee + 1 more
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells

NCT07199569
Conditions
Monkeypox (Mpox)
Interventions
Jynneos, MVA-BN (Quail)
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 49 Years
Enrollment
970 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
10
States / cities
Ames, Iowa • Lenexa, Kansas • Rochester, New York + 7 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase I Trial of an Investigational Small Pox Medication

NCT00728689
Conditions
Orthopoxviral Disease, Smallpox, Monkey Pox
Interventions
ST-246 Days 1 - 3, ST-246 Days 11 - 13
Drug
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Orlando, Florida